Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata

The document discusses the results of two Phase 3 trials of Baricitinib, a Janus Kinase inhibitor, for the treatment of Alopecia Areata. The trials involved a significant number of participants, although the exact number is not specified in the document. The results showed that Baricitinib was effective in treating Alopecia Areata, a condition characterized by hair loss. The drug, marketed as Olumiant®, was subsequently approved for this use. The study was conducted by a team of researchers, including King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R, and the BRAVE-AA Investigators.